Triple therapies plus different probiotics for Helicobacter pylori eradication
This prospective, open-label, pilot study aimed to evaluate the therapeutic role of either Lactobacillus reuteri ATCC 55730 (1 x 10^8 CFU, twice daily) or a multi-strain, high-dose probiotic (2 x 10^10 CFU, twice daily) in addition to standard triple therapies for Helicobacter pylori eradication in 65 consecutive dyspeptic patients with Helicobacter pylori infection.
Patients were assigned to either a standard 7-day triple therapy regimen, a standard 7-day triple therapy regimen + Lactobacillus reuteri supplementation, a standard 7-day triple therapy regimen + multi-strain probiotic, or a 14-day triple therapy regimen + multi-strain probiotic.
No regimen achieved >80% eradication rate. A 14-day therapy plus the multi-strain probiotic tended to achieve a higher eradication rate (71%) although there was no statistically significant differences in terms of eradication rates between the tested regimens (7-day: 62%; 7-day + Lactobacillus reuteri: 53%; 7-day + multi-strain probiotic: 53%). Side-effects were lowest in the 7-day + Lactobacillus reuteri group (6%), but there were no statistically significant differences between the groups (7-day: 27%; 7-day + multi-strain probiotic: 20%; 14-day + probiotic: multi-strain 33%).
Conclusion: 7–14 days triple therapy with or without probiotic supplementations failed to achieve acceptable Helicobacter pylori eradication rates.